Poor prognosis associated with gain of chromosome 1Q21 in multiple myeloma may be overcome by treatment with a bortezomib combination

被引：0
|
作者：
Sagaster, V.
Odelga, V.
Kaufmann, H.
Ackermann, J.
Galhuber, M.
Zojer, N.
Ludwig, H.
Wieser, R.
Zielinski, C.
Drach, J.
机构：
[1] Med Univ Vienna, Vienna, Austria
[2] Wilhelminenspital Stadt Wien, Dept Med 1, Vienna, Austria
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2007年 / 92卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0405
引用
下载
收藏
页码：149 / 149
页数：1
相关论文
共 50 条
  • [1] The combination of C-Myc rearrangement and 1q21 gain is associated with poor prognosis in multiple myeloma
    Yuanyuan Jin
    Xiaochen Yu
    Jianhua Du
    Hui Li
    Wenjiao Tang
    Congwei Jia
    Yunyan Zan
    Miao Chen
    Yanbin Zhang
    Minhong Yu
    Weiqi Rong
    Daobin Zhou
    Junling Zhuang
    Annals of Hematology, 2021, 100 : 1251 - 1260
  • [2] The combination of C-Myc rearrangement and 1q21 gain is associated with poor prognosis in multiple myeloma
    Jin, Yuanyuan
    Yu, Xiaochen
    Du, Jianhua
    Li, Hui
    Tang, Wenjiao
    Jia, Congwei
    Zan, Yunyan
    Chen, Miao
    Zhang, Yanbin
    Yu, Minhong
    Rong, Weiqi
    Zhou, Daobin
    Zhuang, Junling
    ANNALS OF HEMATOLOGY, 2021, 100 (05) : 1251 - 1260
  • [3] The Role of 1q21 Gain on the Prognosis of Multiple Myeloma
    Dong Hui Xing
    Jin Huan Wang
    Zhi Gang Zhao
    Journal of Nutritional Oncology, 2021, 6 (02) : 50 - 56
  • [4] THE POOR PROGNOSIS ASSOCIATED WITH GAIN/AMPLIFICATION OF 1Q21 IN RELAPSED MULTIPLE MYELOMA PATIENTS MAY BE OVERCOME BY VELCADE BASED REGIMEN IN CONTRARY OF THALIDOMIDE BASED REGIMEN
    Nemec, P.
    Greslikova, H.
    Smetana, J.
    Zaoralova, R.
    Kupska, R.
    Berankova, K.
    Filkova, H.
    Kralova, D.
    Krejci, M.
    Pour, L.
    Zahradova, L.
    Sandecka, V.
    Adam, Z.
    Kuglik, P.
    Hajek, R.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 227 - 228
  • [5] Gain/Amplification of Chromosome Arm 1q21 in Multiple Myeloma
    Hanamura, Ichiro
    CANCERS, 2021, 13 (02) : 1 - 16
  • [6] Amplification of 1q21 is associated with poor outcome after treatment with bortezomib in relapsed/refractory multiple myeloma.
    Drach, Johannes
    Sagaster, Verena
    Odelga, Victoria
    Kaufmann, Hannes
    Ackermann, Jutta
    Galhuber, Markus
    Zojer, Niklas
    Kueenburg, Elisabeth
    Zielinski, Christoph
    Wieser, Rotraud
    Ludwig, Heinz
    BLOOD, 2006, 108 (11) : 970A - 971A
  • [7] The impact of bortezomib-based induction in newly diagnosed multiple myeloma with chromosome 1q21 gain
    Tang, Hoi Ki Karen
    Fung, Chi Yeung
    Morgan, Gareth J.
    Kumar, Shaji
    Siu, Lisa
    Alvin, Ho Wan
    Yip, Sze Fai
    Lau, Ka Ngai Harry
    Lau, Chi Kuen
    Lee, Harold
    Leung, Kwan Hung
    Kho, Bonnie
    Wong, Howard
    Ngai, Cheong
    Hwang, Yu Yan
    Sim, Joycelyn
    Kwong, Yok Lam
    Chim, Chor Sang
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022, 13
  • [8] Chromosome 1q21 abnormalities in multiple myeloma
    Schmidt, Timothy M.
    Fonseca, Rafael
    Usmani, Saad Z.
    BLOOD CANCER JOURNAL, 2021, 11 (04)
  • [9] Chromosome 1q21 abnormalities in multiple myeloma
    Timothy M. Schmidt
    Rafael Fonseca
    Saad Z. Usmani
    Blood Cancer Journal, 11
  • [10] Gain of chromosome 1q21: Pathogenesis, prognostication, and treatment of a time-lapsed multiple myeloma
    Hose, D.
    Seckinger, A.
    Meissner, T.
    Hielscher, T.
    Reme, T.
    Moreaux, J.
    Bertsch, U.
    Hillengass, J.
    Jauch, A.
    Goldschmidt, H.
    Neben, K.
    ONKOLOGIE, 2013, 36 : 40 - 41
12345